NCT02251457View on ClinicalTrials.gov

Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

December 18, 2017

Study Completion Date

December 18, 2017

Conditions

Myotonia CongenitaParamyotonia CongenitaMyotonic Dystrophy 1

Interventions

DRUG

Ranolazine

Ranexa is FDA approved for chronic angina

Trial Locations (1)

43221

The Ohio State University Wexner Medical Center, Columbus

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Ohio State University

OTHER

NCT02251457 - Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1 | Biotech Hunter | Biotech Hunter